Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma.
Saved in:
| Title: | Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma. |
|---|---|
| Authors: | Daniel, Adrien1 (AUTHOR) adrien.daniel@chru-lille.fr, Ghez, David2 (AUTHOR), Ravaiau, Camille3 (AUTHOR), Cavalieri, Doriane4 (AUTHOR), Tournilhac, Olivier4 (AUTHOR), Herbaux, Charles5 (AUTHOR), Roriz, Mélanie6 (AUTHOR), Wemeau, Mathieu7 (AUTHOR), Guillet, Stéphanie8 (AUTHOR), Bossard, Jean Baptiste9 (AUTHOR), Hélène, Demarquette10 (AUTHOR), Kaphan, Eleonore11 (AUTHOR), Caroline, Regny12 (AUTHOR), Florence, Lachenal12 (AUTHOR), Pierache, Adeline13 (AUTHOR), Michel, Marc8 (AUTHOR), Godeau, Bertrand8 (AUTHOR), Terriou, Louis14 (AUTHOR) louis.terriou@chru-lille.fr |
| Source: | European Journal of Haematology. Dec2022, Vol. 109 Issue 6, p719-727. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
